Parameter
| Biomarker | KRAS mutations () | Full name | Kirsten rat sarcoma viral oncogene | Molecular Type | Nucleic acid (DNA mutation) |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Diagnosis, prognosis, selection of targeted therapy | ||
| Disease | Cholangiocarcinoma (CCA) | Disease Subtypes | / | ||
| Organ | Bile duct/Liver | Test Sample / Technology Platform | Tissue/plasma/bile (NGS, ddPCR) | ||
| Pathobiological Mechanisms | Mutations such as G12D/V/Q61H activate MAPK pathway and promote tumor proliferation, drug resistance and immunosuppression | ||||
| Clinical Availability Status | Clinical validation/guideline recommendation; The detection rate is high in eCCA | ||||
| Notes and Dynamics | A G12 / G13 mutations suggest poor prognosis shrink (OS), KRAS G12C inhibitors in clinical trials; CtDNA detection sensitivity 80%, specificity of 93% | ||||